Multiple myeloma - lenalidomide
Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Summary
Lenalidomide (used together with a medicine called dexamethasone) is recommended as a possible treatment for people with multiple myeloma who have already had at least two other treatments. The manufacturer of lenalidomide has agreed to cover the cost of the drug for people who stay on treatment for ...
Following the BBC documentary The Price of Life broadcast on 17 June, NICE has published guidance on the use of lenalidomide for multiple myeloma on its website ahead of the scheduled publication date. The guidance will be formally issued to the NHS when we launch other guidance on 24 June 2009. Accordingly, the Secretary of State's direction requiring NHS organisations to make funding available for NICE recommended treatments within 3 months of final guidance being published will begin ON 24 June.
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in October 2010
About this guidance
Technology appraisals TA171
Issued: June 2009
How this guidance was produced